Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Synairgen in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 0.83.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in Synairgen. This N/A consensus rating has held steady for over two years.
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.
Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients to be initiated in hospital and 120 patients to be initiated in the home setting. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
Read More
